PMID- 31064410
OWN - NLM
STAT- MEDLINE
DCOM- 20200130
LR  - 20231011
IS  - 2050-6511 (Electronic)
IS  - 2050-6511 (Linking)
VI  - 20
IP  - 1
DP  - 2019 May 7
TI  - Abatacept induced granulomatous hepatitis with a sarcoidosis- like reaction: a 
      blinded trial in mice.
PG  - 26
LID - 10.1186/s40360-019-0303-0 [doi]
LID - 26
AB  - BACKGROUND: Abatacept is increasingly used for rheumatoid arthritis (RA) and 
      juvenile idiophathic arthritis (JIA) treatment. However little is known about the 
      risk of hepatotoxicity. The aim of this study was to determine whether the 
      inhibition of the T cell CD28 receptor by abatacept results in acute hepatitis in 
      BALB/c mice. METHODS: Twenty BALB/c mice were studied. Ten mice received 
      subcutaneous (SC) injection of abatacept (0.25mg per 25g body weight per 0.03 ml 
      normal saline) at 0, 2, 4 and 8 weeks. For the control group, 10 mice received a 
      SC injection of normal saline (NS) (0.03 ml). At the 10th week post injection, 
      the mice were sacrificed, and histopathological studies were conducted. RESULTS: 
      Of the abatacept-treated group, 3/10 mice died. Liver histology for the 
      abatacept-treated group showed that 6/7 displayed histopathological changes in 
      the lobular cellular infiltrates of eosinophils, lymphocytes and histiocytes, in 
      addition to granuloma formation. In contrast, only minimal inflammation was 
      observed in 3/10 mice in the control group (p=0.036). CONCLUSION: Abatacept may 
      play a role in inducing granulomatous hepatitis with a sarcoidosis-like reaction. 
      Additional data including transaminases, antinuclear antibodies (ANA), 
      Antimitochondrial antibodies (AMA) and other auto antibodies should be tested.
FAU - Almogairen, Sultan M
AU  - Almogairen SM
AUID- ORCID: 0000-0003-2392-6386
AD  - Rheumatology Division, Department of Medicine, College of Medicine, King Saud 
      University, P O Box 2925, Riyadh, 11461, Saudi Arabia. salmogairin@ksu.edu.sa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190507
PL  - England
TA  - BMC Pharmacol Toxicol
JT  - BMC pharmacology & toxicology
JID - 101590449
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antirheumatic Agents)
RN  - 7D0YB67S97 (Abatacept)
SB  - IM
MH  - Abatacept/*adverse effects
MH  - Animals
MH  - Anti-Inflammatory Agents/*adverse effects
MH  - Antirheumatic Agents/*adverse effects
MH  - Granuloma/*chemically induced/pathology
MH  - Hepatitis, Animal/*chemically induced/pathology
MH  - Liver/drug effects/pathology
MH  - Male
MH  - Mice, Inbred BALB C
MH  - Sarcoidosis/*chemically induced/pathology
PMC - PMC6503540
OTO - NOTNLM
OT  - Abatacept
OT  - Granuloma
OT  - Hepatitis
OT  - Sarcoidosis
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study protocol was approved by 
      Research Ethics Committee at the College of Medicine, King Saud University, 
      Riyadh. Consent to participate is not applicable. CONSENT FOR PUBLICATION: Not 
      applicable. COMPETING INTERESTS: The author declares that there are no competing 
      interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to 
      jurisdictional claims in published maps and institutional affiliations.
EDAT- 2019/05/09 06:00
MHDA- 2020/01/31 06:00
PMCR- 2019/05/07
CRDT- 2019/05/09 06:00
PHST- 2018/06/16 00:00 [received]
PHST- 2019/04/22 00:00 [accepted]
PHST- 2019/05/09 06:00 [entrez]
PHST- 2019/05/09 06:00 [pubmed]
PHST- 2020/01/31 06:00 [medline]
PHST- 2019/05/07 00:00 [pmc-release]
AID - 10.1186/s40360-019-0303-0 [pii]
AID - 303 [pii]
AID - 10.1186/s40360-019-0303-0 [doi]
PST - epublish
SO  - BMC Pharmacol Toxicol. 2019 May 7;20(1):26. doi: 10.1186/s40360-019-0303-0.